Eli Lilly and Company (NYSE:LLY) Shares Sold by Vantage Investment Partners LLC

Vantage Investment Partners LLC lessened its position in Eli Lilly and Company (NYSE:LLY) by 8.9% during the third quarter, Holdings Channel reports. The fund owned 16,378 shares of the company’s stock after selling 1,603 shares during the quarter. Eli Lilly and Company comprises approximately 1.2% of Vantage Investment Partners LLC’s investment portfolio, making the stock its 29th largest position. Vantage Investment Partners LLC’s holdings in Eli Lilly and Company were worth $14,510,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Everhart Financial Group Inc. increased its stake in Eli Lilly and Company by 14.1% during the 3rd quarter. Everhart Financial Group Inc. now owns 5,433 shares of the company’s stock valued at $4,813,000 after buying an additional 672 shares during the period. WCM Investment Management LLC increased its stake in Eli Lilly and Company by 14.9% during the 3rd quarter. WCM Investment Management LLC now owns 13,260 shares of the company’s stock valued at $11,639,000 after buying an additional 1,716 shares during the period. Opinicus Capital Inc. increased its stake in Eli Lilly and Company by 1.7% during the 3rd quarter. Opinicus Capital Inc. now owns 3,707 shares of the company’s stock valued at $3,284,000 after buying an additional 61 shares during the period. Nations Financial Group Inc. IA ADV increased its stake in Eli Lilly and Company by 0.8% during the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 6,204 shares of the company’s stock valued at $5,497,000 after buying an additional 51 shares during the period. Finally, tru Independence LLC increased its stake in Eli Lilly and Company by 8.7% during the 3rd quarter. tru Independence LLC now owns 350 shares of the company’s stock valued at $310,000 after buying an additional 28 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.2 %

Shares of LLY stock opened at $833.29 on Tuesday. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The firm’s fifty day simple moving average is $896.31 and its 200 day simple moving average is $869.34. The firm has a market capitalization of $791.06 billion, a P/E ratio of 90.09, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period last year, the firm earned $0.10 EPS. The company’s quarterly revenue was up 20.4% compared to the same quarter last year. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.62%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LLY. Bank of America lowered their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Finally, Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,008.41.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.